Bio-Connect

Protein Of Interest (POI): CD3 Bridging Chemiluminescent Assay Kit

82818
BPS Bioscience
Product group Assays
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    BPS Bioscience
  • Product Name
    Protein Of Interest (POI): CD3 Bridging Chemiluminescent Assay Kit
  • Delivery Days Customer
    23
  • Applications
    Other Application
  • Certification
    Research Use Only
  • Scientific Description
    The Protein Of Interest (POI): CD3 Bridging Chemiluminescent Assay Kit is an ELISA designed to analyze the ability of a Bispecific Antibody (BsAbs) to POI and CD3 (cluster of differentiation 3) for screening and profiling applications. This assay allows to study the simultaneous binding to CD3 and to a protein/antigen of interest of bispecific antibodies. The protein of interest must be provided by the user. The Protein of Interest (POI): CD3 Bridging Chemiluminescent Assay Kit comes with enough CD3-Containing Detection Reagent, assay buffers and controls (reference capture antigen (BCMA protein) and reference bispecific antibody (targeting BCMA)) for 100 reactions. This kit provides the user with the flexibility to test their own specific POI, compare variants, or assay several POIs at once for specific determination or epitope mapping, using an optimized protocol and CD3 reagent. The native state of the POI, optimal concentration to be used in plate coating, and ability to be recognized by the test antibodies should be assessed prior the testing with this assay kit. Figure 1: Protein Of Interest (POI): CD3 Bridging Chemiluminescent Assay Kit assay principle First a 96-well plate is coated with POI and blocked. Next, bispecific antibodies are added in an optimized assay buffer. This is followed by washing to remove any unbound bispecific antibodies, and the plate is incubated with CD3-Containing Detection Reagent. Finally, ELISA ECL substrate is added and the chemiluminescence generated can be measured using a chemiluminescence reader. The chemiluminescence signal is proportional to the efficacy of the bridging. Need us to run inhibitor screens or profile your bispecific antibodies towards CD3 and BCMA? Check out our Immunotherapy Biochemical Screening Services.
  • Storage Instruction
    See manual
  • UNSPSC
    41116158